联系方式

电话:010-62797881

邮箱:zhangyonghui@tsinghua.edu.cn

张永辉 博士

张永辉现为清华大学药学院长聘教授,清华北大生命科学联合中心研究员,博士生导师,英国皇家化学会会士(FRSC),同时担任RSC Medicinal Chemistry副主编。曾获教育部“长江学者”特聘教授,树兰医学青年奖(2019)以及天津市自然科学奖二等奖(2020)。张永辉教授长期专注于免疫药学领域的研究,探讨代谢对免疫系统的调控机制。包括首次提出了针对脂质代谢发展新型疫苗佐剂,同时揭示了γδ T细胞受体通过靶细胞BTN蛋白识别细胞内脂质代谢产物的分子机制。这些研究从代谢调控免疫的角度开拓了疫苗和细胞治疗的新领域。

个人履历

2024-至今 清华大学药学院 长聘教授

2019-2024 清华大学药学院 长聘副教授

2013-2016 清华大学医学院、药学院 助理教授

2006-2013 University of Illinois at Urbana-Champaign 讲师

2002-2005 University of Illinois at Urbana-Champaign 博士后

1999-2002 中国科学院上海有机化学研究所 博士

1996-1999 大连理工大学 硕士

1992-1996 江苏海洋大学 学士

主要科研领域与方向

张永辉实验室专注于免疫药学领域,涵盖免疫治疗的基础理论、新药物分子的发现及新型疾病治疗方案的探索。具体研究方向包括:(1)免疫代谢;(2)γδ-T细胞免疫识别机制;(3)新机制疫苗;(4)免疫治疗新策略;(5)非传统抗感染策略研究。

代表性论文

(1)Yuan, L., Ma, X., Yang, Y. et al. Zhang, Y.* Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells. Nature 2023, 621, 840–848. 


(2)Lin, F., Li, J., Xie, Y., Zhu, J.,Nguye, T., Zhang, Y*. Zhu, J*., Spring*. T. A general chemical principle for creating closure-stabilizing integrin inhibitors. Cell, 2022, 185, 3533-3550. 


(3)Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., Du, Y., Chen, C. Guo, R*. Zhang, Y*. KRAS (G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery 2022, 8, 5.


(4)Yang, Y., Li, L., Zhou, X., Duan, J., Liu, W., Chen, C., Wang, L., Li, X., Cai, N., Yuan, L., Chen, J., Kang, N., Malwal, S.R., Shi, Y., Oldfield, E*., Guo, R-T*., Zhang, Y*. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen mediated Vγ9Vδ 2 T cell activation. Immunity, 2019, 50, 1043-1053.


(5)Xia, Y., Xie, Y., Yu, Z., Xiao, H., Jiang, G., Zhou, X., Yang, Y., Li, X., Zhao, M., Li, L., Zheng, M., Han, S., Zong, Z., Meng, X., Deng, H., Ye, H., Fa, Y., Wu, H., Oldfield, E., Hu, X., Liu, W*., Shi, Y*., Zhang, Y*. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell, 2018, 175, 1059-1073.


(6)Cai, N., Han, S., Zhang, Y*. Docking complete: a step further toward the holy grail of γδ T cell biology. Immunity, 2019, 51, 781-783. 


(7)Han, S., Li, X., Xia, Y., Yu, Z., Cai, N., Malwal, S., Han, X., E. Oldfield*., Zhang, Y*. Farnesyl pyrophosphate synthase as a target for drug development: discovery of natural-product-derived inhibitors and their activity in pancreatic cancer cells. J. Med. Chem. 2019, 62, 10867-10896.


(8)Xia, Y., Liu, Y-L., Xie, Y., Zhu, W., Guerra, F., Shen, S., Yeddula, N., Fischer, W., Low, W., Zhou, X., Zhang, Y*., Oldfield, E*., Verma, I. M*. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci. Trans. Med. 2014,263ra261.